Valproate‐induced hepatic steatogenesis in rats

James H. Lewis; Hyman J. Zimmerman; Carlton T. Garrett; Elliot Rosenberg

doi:10.1002/hep.1840020622

Valproate‐induced hepatic steatogenesis in rats

James H. Lewis, Hyman J. Zimmerman, Carlton T. Garrett, Elliot Rosenberg

Research output: Contribution to journal › Article › peer-review

Abstract

The administration of high‐dose valproic acid (VPA) (750 mg per kg) consistently produced significant microvesicular steatosis in mature Sprague‐Dawley rats after 48 hr. Similar changes occurred in animals pretreated with phenobarbital which received a lower dose of VPA (350 mg per kg), but no steatosis was seen in animals treated with the low‐dose VPA alone. The steatogenic effect of VPA is most likely mediated by a toxic metabolite. It can also be speculated that phenobarbital, by enhancing the inducing effects of the hepatic mixed‐function oxidase system, may lead to increased conversion of VPA to a toxic metabolite. Young and weanling rats appeared to be resistant to the steatogenic effects of VPA. Reproduction of microvesicular steatosis in this experimental model may permit exploration of factors that enhance or inhibit VPA‐induced hepatic injury.

Original language	English
Pages (from-to)	870-873
Number of pages	4
Journal	Hepatology
Volume	2
Issue number	6
DOIs	https://doi.org/10.1002/hep.1840020622
State	Published - 1982
Externally published	Yes

ASJC Scopus subject areas

Hepatology

Access to Document

10.1002/hep.1840020622

Cite this

@article{33d1d1ac7d554bddae4c650efc90542c,

title = "Valproate‐induced hepatic steatogenesis in rats",

abstract = "The administration of high‐dose valproic acid (VPA) (750 mg per kg) consistently produced significant microvesicular steatosis in mature Sprague‐Dawley rats after 48 hr. Similar changes occurred in animals pretreated with phenobarbital which received a lower dose of VPA (350 mg per kg), but no steatosis was seen in animals treated with the low‐dose VPA alone. The steatogenic effect of VPA is most likely mediated by a toxic metabolite. It can also be speculated that phenobarbital, by enhancing the inducing effects of the hepatic mixed‐function oxidase system, may lead to increased conversion of VPA to a toxic metabolite. Young and weanling rats appeared to be resistant to the steatogenic effects of VPA. Reproduction of microvesicular steatosis in this experimental model may permit exploration of factors that enhance or inhibit VPA‐induced hepatic injury.",

author = "Lewis, {James H.} and Zimmerman, {Hyman J.} and Garrett, {Carlton T.} and Elliot Rosenberg",

year = "1982",

doi = "10.1002/hep.1840020622",

language = "English",

volume = "2",

pages = "870--873",

journal = "Hepatology",

issn = "0270-9139",

publisher = "John Wiley and Sons Ltd",

number = "6",

}

TY - JOUR

T1 - Valproate‐induced hepatic steatogenesis in rats

AU - Lewis, James H.

AU - Zimmerman, Hyman J.

AU - Garrett, Carlton T.

AU - Rosenberg, Elliot

PY - 1982

Y1 - 1982

N2 - The administration of high‐dose valproic acid (VPA) (750 mg per kg) consistently produced significant microvesicular steatosis in mature Sprague‐Dawley rats after 48 hr. Similar changes occurred in animals pretreated with phenobarbital which received a lower dose of VPA (350 mg per kg), but no steatosis was seen in animals treated with the low‐dose VPA alone. The steatogenic effect of VPA is most likely mediated by a toxic metabolite. It can also be speculated that phenobarbital, by enhancing the inducing effects of the hepatic mixed‐function oxidase system, may lead to increased conversion of VPA to a toxic metabolite. Young and weanling rats appeared to be resistant to the steatogenic effects of VPA. Reproduction of microvesicular steatosis in this experimental model may permit exploration of factors that enhance or inhibit VPA‐induced hepatic injury.

AB - The administration of high‐dose valproic acid (VPA) (750 mg per kg) consistently produced significant microvesicular steatosis in mature Sprague‐Dawley rats after 48 hr. Similar changes occurred in animals pretreated with phenobarbital which received a lower dose of VPA (350 mg per kg), but no steatosis was seen in animals treated with the low‐dose VPA alone. The steatogenic effect of VPA is most likely mediated by a toxic metabolite. It can also be speculated that phenobarbital, by enhancing the inducing effects of the hepatic mixed‐function oxidase system, may lead to increased conversion of VPA to a toxic metabolite. Young and weanling rats appeared to be resistant to the steatogenic effects of VPA. Reproduction of microvesicular steatosis in this experimental model may permit exploration of factors that enhance or inhibit VPA‐induced hepatic injury.

UR - http://www.scopus.com/inward/record.url?scp=0020361361&partnerID=8YFLogxK

U2 - 10.1002/hep.1840020622

DO - 10.1002/hep.1840020622

M3 - Article

C2 - 6815046

AN - SCOPUS:0020361361

SN - 0270-9139

VL - 2

SP - 870

EP - 873

JO - Hepatology

JF - Hepatology

IS - 6

ER -

Valproate‐induced hepatic steatogenesis in rats

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this